Results 101 to 110 of about 758,251 (341)

Microphysiological Systems of Lymphatics and Immune Organs

open access: yesAdvanced Healthcare Materials, EarlyView.
This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain   +2 more
wiley   +1 more source

Adverse Effects of Glyphosate and Microcystin-LR on Fish Health: Evidence from Structural and Functional Impairments in Zebrafish Gills

open access: yesAnimals
Glyphosate (GLY) and microcystin-LR (MC-LR) frequently co-occur in natural water bodies. In this study, a subacute exposure test was conducted on zebrafish treated with 3.5 mg/L GLY and 35 μg/L MC-LR, individually and in combination, for 21 d to ...
Yidan Zhang   +5 more
doaj   +1 more source

Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections

open access: yesCanadian Journal of Infectious Diseases, 1992
Biological response modifiers (BRMs) have particular promise when used in combination with more standard antiviral agents for treatment of viral diseases.
Robert W Sidwell   +6 more
doaj   +1 more source

Development of a Surrogate Neutralization Assay for Norovirus Vaccine Evaluation at the Cellular Level

open access: yesViruses, 2018
Noroviruses (NoVs) are the main pathogens responsible for sporadic and epidemic nonbacterial gastroenteritis, causing an estimated 219,000 deaths annually worldwide.
Xiaoli Wang   +6 more
doaj   +1 more source

Avidity of influenza-specific memory CD8+ T-cell populations decays over time compromising antiviral immunity [PDF]

open access: yes, 2012
Decline of cell-mediated immunity is often attributed to decaying T-cell numbers and their distribution in peripheral organs. This study examined the hypothesis that qualitative as well as quantitative changes contribute to the declining efficacy of CD8+
Alexander-Miller   +41 more
core   +1 more source

Antiviral Treatments

open access: yesClinics in Chest Medicine, 2017
Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract.
openaire   +2 more sources

Multivalent Protein Nanorings for Broad and Potent SARS‐CoV‐2 Neutralization

open access: yesAdvanced Healthcare Materials, EarlyView.
A protein‐only, modular multivalent nanoscaffold displaying 20 anchor points, decorated with two different binders (10 of each), targeting the SARS‐CoV‐2 receptor‐binding domain is presented. The construct self‐assembles into stable, biocompatible, homogeneous nanoparticles, exhibit synergistic binding with fM IC50 values. It also detects spike at 9 ng 
Molood Behbahanipour   +11 more
wiley   +1 more source

Coxsackievirus A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor

open access: yesEmerging Microbes and Infections, 2017
Coxsackievirus A16 (CVA16) is one of the major pathogens responsible for hand, foot and mouth disease, which affects more than two million children in the Asian-Pacific region annually.
Xueyang Zhang   +6 more
doaj   +1 more source

Redefining Therapies for Drug‐Resistant Tuberculosis: Synergistic Effects of Antimicrobial Peptides, Nanotechnology, and Computational Design

open access: yesAdvanced Healthcare Materials, EarlyView.
Antimicrobial peptide (AMP)‐loaded nanocarriers provide a multifunctional strategy to combat drug‐resistant Mycobacterium tuberculosis. By enhancing intracellular delivery, bypassing efflux pumps, and disrupting bacterial membranes, this platform restores phagolysosome fusion and macrophage function.
Christian S. Carnero Canales   +11 more
wiley   +1 more source

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

open access: yesAdvanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy